Ahmedabad: With the Novartis Blockbuster Vildagliptin going off patent, Zydus Cadila has taken made its move towards affordable diabetes care in India...
News
CDSCO approves over 3000 global clinical trial sites, investigators; prepares comprehensive database
CDSCO is preparing a comprehensive database of sites and investigators involved in the conduct of the clinical trial in different therapeutic categori...
Subscription of Piramal debentures by Canadian investor approved by CCI
The Competition Commission of India (CCI) in a tweet said it “approves the subscription of CCDs of Piramal Enterprises by CDPQ. Upon conversion,...
Merck to acquire cancer drug developer ArQule for USD 2.7 billion
New Delhi: Merck, known as MSD outside the United States and Canada, and ArQule, Inc. recently announced that the companies have entered into a defini...
Transasia Bio-Medicals names Medtronic biz director Ravi Kaushik as new CEO
Prior to this appointment at Transasia Bio-Medicals, Ravi Kaushik was Group Marketing Director – Asia Pacific & Country Business Director &#...
Sanofi closes research in diabetes, cardiovascular diseases; narrows units to spur profit
Sanofi, which is due to further detail strategic plans to investors on Tuesday in Cambridge, Massachusetts, said it was targeting new cost savings of ...
SETBACK: Correvio Pharma heart drug Brinavess fails to win USFDA panel backing
The panel voted 11-2 against approving Correvio Pharma’s drug, Brinavess, citing serious safety risks, including low blood pressure and irregula...
Biohaven Pharma Alzheimers treatment Troriluzole to continue late-stage study
Biohaven Pharmaceutical’s study of its experimental Alzheimer’s treatment, Troriluzole is being led by the Alzheimer’s Disease Coope...
Roche secures CE Mark for Accu-Chek SugarView app for diabetes management
Now officially classified as in-vitro diagnostics (IVD) software, the app will be made widely accessible by Roche first for certain smartphone models ...
Dr Reddys unveils generic Deferasirox Tablets in US
The two different products launched by Dr Reddy’s Labs in the US market are generic versions of Exjade (deferasirox) and Jadenu (deferasirox) in...
